Search review questions

Adverse effects · people with acute hordeolum

Resolution of hordeolum at short term · people with acute hordeolum

Resolution of hordeolum between 8 and 30 days after diagnosis, or that closest to 14 days after diagnosis · people with acute hordeolum

Uncorrected visual acuity (UCVA) of 20/20 or better · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Uncorrected visual acuity (UCVA) of 20/40 or better · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Proportion of participants who lost two or more lines of best‐corrected visual acuity (BCVA) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Eyes within ± 0.5 D of target refraction · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Postoperative corneal haze · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Postoperative pain score: 1 year · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Adverse events (flap‐complications) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Treatment success (at 6 months) · children with congenital nasolacrimal duct obstruction (NLDO)

Treatment success (at other time points) · children with congenital nasolacrimal duct obstruction (NLDO)

Proportion of participants requiring secondary procedures · children with congenital nasolacrimal duct obstruction (NLDO)

Cost‐effectiveness · children with congenital nasolacrimal duct obstruction (NLDO)

Complications · children with congenital nasolacrimal duct obstruction (NLDO)

Change in the prevalence of cataract blindness · people with vision impairment caused by cataract

Service utilisation: uptake of referral · people with vision impairment caused by cataract

Service utilisation: uptake of surgery · people with vision impairment caused by cataract

Cataract Surgical Coverage · people with vision impairment caused by cataract

Surgical outcome (visual acuity in the operated eye) · people with vision impairment caused by cataract

Adverse events · people with vision impairment caused by cataract

Prevalence of visual impairment due to cataract · people with vision impairment caused by cataract

Service utilisation: uptake of referral · people with vision impairment caused by cataract

Service utilisation: uptake of surgery · people with vision impairment caused by cataract

Cataract Surgical Coverage · people with vision impairment caused by cataract

Surgical outcome (visual acuity in the operated eye) · people with vision impairment caused by cataract

Adverse events · people with vision impairment caused by cataract

Change in the prevalence of cataract blindness · people with vision impairment caused by cataract

Prevalence of visual impairment due to cataract · people with vision impairment caused by cataract

Complete release of vitreous adhesion · people with symptomatic vitreomacular adhesion

Closure of macular hole · people with symptomatic vitreomacular adhesion

Complete posterior vitreous detachment · people with symptomatic vitreomacular adhesion

3‐line or greater improvement in best‐corrected visual acuity · people with symptomatic vitreomacular adhesion

Requirement for vitrectomy · people with symptomatic vitreomacular adhesion

Mean change in validated visual function questionnaire score from baseline Score ranges from 0 to 100, higher scores are better visual function · people with symptomatic vitreomacular adhesion

Any ocular adverse event · people with symptomatic vitreomacular adhesion

Improvement in symptoms, reported by the child or by their parents/carers, preferably measured by a validated tool, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis

Elimination of all clinical signs of ocular surface inflammation ('complete success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis

Improvement of clinical signs of ocular surface inflammation ('partial success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis

Change from baseline in best corrected visual acuity in affected eye(s) in logMAR · children with blepharokeratoconjunctivitis

Uncontrolled or poorly controlled disease progression due to treatment failure, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis

Adverse effects of medication, at any time during treatment · children with blepharokeratoconjunctivitis

Quality of life · children with blepharokeratoconjunctivitis

Proportion of participants with postoperative surgical success (hypertropia less than 3 PD in primary gaze) · people with symptom‐producing and/or socially noticeable unilateral overacting inferior oblique muscle; all…

Proportion of participants with postoperative hypertropia less than 3 PD in down gaze · people with unilateral superior oblique palsy

Proportion of participants with postoperative hypertropia less than 3 PD in contralateral gaze · people with unilateral superior oblique palsy

Proportion of participants who received additional strabismus surgery · people with unilateral superior oblique palsy

Proportion of participants with reversal of vertical deviation postoperatively · people with unilateral superior oblique palsy

Proportion of participants with postoperative orbital cellulitis · people with unilateral superior oblique palsy

Proportion of participants with anomalous head position preoperatively with residual head tilt postoperatively · people with symptom‐producing and/or socially noticeable unilateral overacting inferior oblique muscle; all…